Prognostic Relevance of Relative Ellipsoid Zone Reflectivity for Ellipsoid Zone Loss in Macular Telangiectasia Type 2
This study demonstrates the prognostic relevance of spatially refined rEZR changes before and beyond already existing EZ loss for both its onset and progression over time in MacTel. Further analyses of the rEZR are warranted to achieve both a more tailored patient selection and a novel end point identification for clinical trials in MacTel.
Authors
- Lukas Goerdt (ORCID: https://orcid.org/0000-0002-3193-3829)
- Leonie Weinhold (ORCID: https://orcid.org/0000-0002-9194-9427)
- Frank Gerhard Holz (ORCID: https://orcid.org/0000-0001-8019-9272)
- Matthias Schmid (ORCID: https://orcid.org/0000-0002-0788-0317)
- Sarah Thiele (ORCID: https://orcid.org/0000-0002-1123-6700)
- Sandrine H. Künzel (ORCID: https://orcid.org/0000-0002-1686-4642)
- Kristina Pfau (ORCID: https://orcid.org/0000-0002-3642-3502)
- Kristin Raming (ORCID: https://orcid.org/0000-0003-1133-8675)
- Ben Isselmann
- Simone Tzaridis (ORCID: https://orcid.org/0000-0002-8380-6485)
- José Luis Rodríguez García (ORCID: https://orcid.org/0009-0003-1161-1931)
Institutions
- Scripps Research Institute (US)
- University of Bonn (DE)
- Universität Hamburg (DE)
- University of Basel (CH)
- University of Alabama at Birmingham (US)
- Institut für Medizinische Biometrie, Informatik und Epidemiologie (DE)
- The Lowy Medical Research Institute (US)
- University Medical Center Hamburg-Eppendorf (DE)
Publication Details
- Journal
- Investigative Ophthalmology & Visual Science
- Published
- 2024-12-26
- DOI
- https://doi.org/10.1167/iovs.65.14.36
- Citations
- 2
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.08
Funders
- Bayer
- Alexion Pharmaceuticals
- NightstaRx
- Apellis Pharmaceuticals
- Deutsche Forschungsgemeinschaft
- Astellas Pharma
- Heidelberg Engineering
- Genentech
- Allergan
- Novartis Pharma
- Daiichi Sankyo Europe